Scientific Program

Thursday, September 19, 2019

Hall A
13:30-15:40 Hematology hot news session: advances in disease biology
Chairs: Irene Ghobrial, USA; Arnon Nagler, Israel
13:30-14:00 Introduction to IACH activities and projects
Mohamad Mohty, France; Arnon Nagler, Israel
14:00-14:20 Waldenstrom macroglobulinemia
Irene Ghobrial, USA
14:20-14:40 New insights in NPM1-1 mutated AML
Brunangelo Falini, Italy
14:40-15:00 Myelodysplastic syndromes
Ghulam Mufti, UK
15:00-15:20 Multiple myeloma
Robert Orlowski, USA
15:20-15:40 ITP
Jenny Despotovic, USA
15:40-16:00 Coffee Break
16:00-17:30 Plenary Session 1: Advances in hematology
Chairs: Mohamad Mohty, France; He Huang, China
16:00-16:20 Current recommendation for TKI cessation in chronic myeloid leukemia (CML)
Francois Guilhot, France
16:20-16:40 CAR T cells: experience from China
He Huang, China
16:40-17:00 Next generation CAR T cells
Saad Kenderian, USA
17:00-17:30 Chronic lymphocytic leukemia: state-of-the-art therapy
Gianluca Gaidano, Italy
17:30-17:45 Short Break
17:45-18:30 Opening Session: Keynote opening lecture and award presentation
Chairs: Mohamad Mohty, France; Arnon Nagler, Israel
17:45-18:00 Presentation of the H.J. Khoury excellence in research award
18:00-18:30 Management of elderly myeloma: 30 years of active research
Thierry Facon, France
18:30-19:30 Welcome Reception

Friday, September 20, 2019

Hall A Hall B
09:00-10:30 Session F1A: Multiple myeloma
Chairs: Thierry Facon, France; Meral Beksaç, Turkey
09:00-10:30 Session F1B: Allogeneic stem cell transplant indications and results
Chairs: Ibrahim Yakoub-Agha, France; Jordi Sierra, Spain
09:00-09:20 Management of elderly myeloma
Thierry Facon, France
09:00-09:20 Acute lymphoblastic leukemia
Sebastian Giebel, Poland
09:20-09:40 Management of transplant-eligible myeloma
Mohamad Mohty, France
09:20-09:40 Acute myeloid leukemia
Arnon Nagler, Israel
09:40-10:00 Management of extra-medullary and high-risk myeloma
Artur Jurczyszyn, Poland
09:40-10:00 Myelodysplastic syndromes
Ibrahim Yakoub-Agha, France
10:00-10:20 Relapsed myeloma
Meral Beksaç, Turkey
10:00-10:20 Myeloproliferative neoplasms
Naveen Pemmaraju, USA
10:20-10:30 Discussion 10:20-10:30 Discussion
10:30-10:45 Short Break
10:45-12:15 Driving a change in outcomes for high-risk AML* and hepatic veno-occlusive disease
*High-risk AML defined as therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
Industry-supported Lunch Symposium (Hall A)
12:15-12:45 Lunch Break
12:45-14:15 Session F2A: Myeloid diseases – Non-transplant approaches
Chairs: Thomas Prebet, USA; Naveen Pemmaraju, USA
12:45-14:15 Session F2B: Long-term complications and supportive care
Chairs: Rafael Duarte, Spain; Didier Blaise, France
12:45-13:05 APL
Miguel A. Sanz, Spain
12:45-13:05 Management of CMV infections
Rafael Duarte, Spain
13:05-13:25 Risk stratification in AML
François Delhommeau, France
13:05-13:25 Late events after reduced-intensity conditioning
Avichai Shimoni, Israel
13:25-13:45 Management of elderly AML
Thomas Prebet, USA
13:25-13:45 Coronary and artery disease
Minoo Battiwalla, USA
13:45-14:05 Management of young AML (outside transplant)
Jordi Sierra, Spain
13:45-14:05 Long-term complications after HCT
Minoo Battiwalla, USA
14:05-14:15 Discussion 14:05-14:15 Discussion
14:15-14:45 Break, Poster Viewing and Visit Exhibition
14:45-16:15 Session F3A: Non-Hodgkin lymphoma
Chairs: Mohamed Kharfan-Dabaja, USA; Ali Bazarbachi, Lebanon
14:45-16:15 Session F3B: Allogeneic stem cell transplant complications
Chairs: Gonzalo Gutiérrez García, Spain; Mutlu Arat, Turkey
14:45-15:05 Mantle cell lymphoma
Olivier Hermine, France
14:45-15:05 Endothelium-related complications
Gonzalo Gutiérrez García, Spain
15:05-15:25 High-grade lymphoma
Christian Gisselbrecht, France
15:05-15:25 How I prevent GVHD
Samer Al-Homsi, USA
15:25-15:45 Indolent lymphoma
Olivier Hermine, France
15:25-15:45 Therapy of acute GVHD
Ernst Holler, Germany
15:45-16:05 Chronic lymphocytic leukemia
Mohamed Kharfan-Dabaja, USA
15:45-16:05 Challenges in chronic GVHD clinical trials
Iskra Pusic, USA
16:05-16:15 Discussion 16:05-16:15 Discussion
16:15-16:30 Coffee Break, Poster Viewing and Visit Exhibition
16:30-18:00 Session F4A: Acute lymphoblastic leukemia (ALL)
Chairs: Hagop Kantarjian, USA; Sebastian Giebel, Poland
16:30-18:00 Session F4B: Advances in allogeneic stem cell transplantation
Chairs: Didier Blaise, France; Avichai Shimoni, Israel
16:30-16:50 CAR T cells in ALL
Jordan Gauthier, USA
16:30-16:50 Haplo-identical versus unrelated and mismatched donors
Giorgia Battipaglia, France
16:50-17:10 Novel antibodies in relapsed/refractory ALL
Eolia Brissot, France
16:50-17:10 Conditioning for haplo-identical transplantation
Didier Blaise, France
17:10-17:30 Which intensity of therapy is required in ALL?
Dieter Hoelzer, Germany
17:10-17:30 Role of the microbiota
Florent Malard, France
17:30-17:50 Management of elderly ALL
Hagop Kantarjian, USA
17:30-17:50 Ex-vivo expansion for cord blood transplantation
Annalisa Ruggeri, France
17:50-18:00 Discussion 17:50-18:00 Discussion
18:00-19:00 Session F5A: MRD in hematologic malignancies
Chairs: Christopher Hourigan, USA; Eolia Brissot, France
18:00-19:00 Session F5B: Case report forum
Chairs: Mohamad Mohty, France; Michael Byrne, USA
18:00-18:20 Current status in CLL
Ilaria Del Giudice, Italy
18:00-18:20 How to write a good paper
Junia Melo, Australia
18:20-18:40 Current status in AML
Christopher Hourigan, USA
18:20-18:40 A complex transplant case (1)
Jean El-Cheikh, Lebanon
18:40-19:00 Current status in ALL
Eolia Brissot, France
18:30-18:40 A complex transplant case (2)
Bhagirathbhai Dholaria, USA
18:40-18:50 Barriers to clinical trial enrollment in HSCT
Michael Byrne, USA
18:50-19:00 Discussion

Saturday, September 21, 2019

Hall A Hall B
08:00-09:00 Session S1A: Transfusion medicine and haemostasis
Chairs: James Bussel, USA; Stephane Giraudier, France
08:00-09:00 Session S1B: Red blood cell disorders
Chair: Pierre Brissot, France
08:00-08:30 Massive bleeding – which recipe?
Pierre Pasquier, France
08:00-08:20 Iron deficiency anemia
Maria Domenica Cappellini, Italy
08:30-09:00 Diagnosis of ITP
James Bussel, USA
08:20-08:40 Thalassemia
Maria Domenica Cappellini, Italy
08:40-09:00 Sickle cell disease
Selim Corbacioglu, Germany
09:00-10:00 Session S2A: Platelet disorders
Chairs: James Bussel, USA; Stephane Giraudier, France
09:00-10:00 Session S2B: Iron-related disorders
Chair: Pierre Brissot, France
09:00-09:30 Management of ET
Stephane Giraudier, France
09:00-09:20 Hepcidin, the “iron hormone”: update on its regulation
Laura Silvestri, Italy
09:30-10:00 Secondary ITP: the game changers
James Bussel, USA
09:20-09:40 Hereditary aceruloplasminemia
Olivier Loréal, France
09:40-10:00 Plasma transferrin saturation: revisiting its importance and interpretation
Pierre Brissot, France
10:00-10:30 Coffee Break, Poster Viewing and Visit Exhibition
10:30-11:30 Session S3A: Management of aplastic anemia, MDS and sAML
Chairs: Thomas Cluzeau, France; Elena Solomou, Greece
10:30-11:30 Session S3B: Toxicities in HSCT
Chairs: Navneet Majhail, USA; Brian Engelhardt, USA
10:30-10:50 Aplastic anemia
Carlos Vallejo, Spain
10:30-10:50 Iron toxicity
Emanuele Angelucci, Italy
10:50-11:10 Low risk MDS
Thomas Cluzeau, France
10:50-11:10 Cardiac toxicity
Rémy Duléry, France
11:10-11:30 Secondary AML
Yngvar Fløisand, Norway
11:10-11:30 Psychosocial complications
Navneet Majhail, USA
11:30-11:45 Short Break
11:45-12:45 CAR T cells in lymphoid malignancies: current status and perspectives
Non-profit Lunch Symposium (Hall A)

12:45-13:15 Lunch Break
13:15-14:15 Session S4A: Management of Hodgkin lymphoma and rare T cell NHLs
Chairs: Ali Bazarbachi, Lebanon; Owen A. O’Connor, USA
13:15-14:15 Session S4B: Immunology of HSCT – Clinical implications
Chairs: Rémy Duléry, France; Yngvar Fløisand, Norway
13:15-13:35 T cell NHL
Owen A. O’Connor, USA
13:15-13:35 Post-Cy as a platform for GVHD prevention
Leonido Luznik, USA
13:35-13:55 How I manage relapsed Hodgkin lymphoma
Anas Younes, USA
13:35-13:55 Predicting immunometabolic complications
Brian Engelhardt, USA
13:55-14:15 Allotransplant for relapsed Hodgkin lymphoma
Ali Bazarbachi, Lebanon
13:55-14:15 Novel approaches in the management of refractory chronic GVHD
Zinaida Perić, Croatia
14:15-14:45 Break, Poster Viewing and Visit Exhibition
14:45-16:15 Session S5A: Clinical experiences from around the world
Chair: Shinichiro Okamoto, Japan
14:45-16:15 Session S5B: Making the right diagnosis in hematology
Chairs: Elad Jacoby, Israel; Florent Malard, France
14:45-15:00 Optimizing resources for bone marrow transplantation
Gregorio Jaimovich, Argentina
14:45-15:00 Mastocytosis
Gandhi Damaj, France
15:00-15:15 Establishment of National Donor Registry and impact on transplant kinetics and outcome: TURKOK experience 2015-2018
Mutlu Arat, Turkey
15:00-15:15 CRS after CAR T cells therapy
Elad Jacoby, Israel
15:15-15:30 Late complications after allogeneic stem cell transplantation
Shinichiro Okamoto, Japan
15:15-15:30 Venous thromboembolism: update on prevention and treatment
Grigorios Gerotziafas, France
15:30-15:45 Multiple myeloma: relapse after autologous stem cell transplantation – incidence, pattern, risk factors and clinical significance
Lalit Kumar, India
15:30-15:45 Leucopenia
Elena Solomou, Greece
15:45-16:00 High-dose TEAM chemotherapy followed by autologous PBSCT in lymphoma
Ahmad Ibrahim, Lebanon
15:45-16:00 Role of artificial intelligence: machine learning in diagnostic hematology
Shahrukh Hashmi, USA
16:00-16:15 Discussion 16:00-16:15 Machine learning-based algorithms
Aziz Nazha, USA
16:15-16:45 Coffee Break, Poster Viewing and Visit Exhibition
16:45-18:30 Plenary Session 2: State-of-the-art management of …
Chairs: Jean-Luc Harousseau, France; Anas Younes, USA
16:45-17:15 … acute lymphoblastic leukemia
Hagop Kantarjian, USA
17:15-17:45 … multiple myeloma
Jean-Luc Harousseau, France
17:45-18:15 … precision medicine and immunotherapy in non-Hodgkin lymphoma
Anas Younes, USA
18:15-18:30 Discussion
18:30 Meeting conclusions and closure
Mohamad Mohty
, France; Arnon Nagler, Israel